166 related articles for article (PubMed ID: 1854617)
1. The influence of serum methotrexate concentrations and drug dosage on outcome in childhood acute lymphoblastic leukaemia.
Pearson AD; Amineddine HA; Yule M; Mills S; Long DR; Craft AW; Chessells JM
Br J Cancer; 1991 Jul; 64(1):169-73. PubMed ID: 1854617
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
Martelli N; Mathieu O; Margueritte G; Bozonnat MC; Daurès JP; Bressolle F; Hillaire-Buys D; Peyrière H
J Clin Pharm Ther; 2011 Apr; 36(2):237-45. PubMed ID: 21366654
[TBL] [Abstract][Full Text] [Related]
3. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
4. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.
Schmiegelow K; Schrøder H; Gustafsson G; Kristinsson J; Glomstein A; Salmi T; Wranne L
J Clin Oncol; 1995 Feb; 13(2):345-51. PubMed ID: 7531219
[TBL] [Abstract][Full Text] [Related]
5. Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Schmiegelow K; Ifversen M
Pediatr Hematol Oncol; 1996; 13(5):433-41. PubMed ID: 10897815
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia.
Pearson AD; Mills S; Amineddine HA; Long DR; Craft AW; Chessells JM
Cancer Chemother Pharmacol; 1987; 20(3):243-7. PubMed ID: 3315283
[TBL] [Abstract][Full Text] [Related]
7. Oral methotrexate is as effective as intramuscular in maintenance therapy of acute lymphoblastic leukaemia.
Chessells JM; Leiper AD; Tiedemann K; Hardisty RM; Richards S
Arch Dis Child; 1987 Feb; 62(2):172-6. PubMed ID: 3469936
[TBL] [Abstract][Full Text] [Related]
8. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
9. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia.
Schmiegelow K
Pediatr Hematol Oncol; 1991; 8(4):301-12. PubMed ID: 1782110
[TBL] [Abstract][Full Text] [Related]
12. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
13. Disposition of oral methotrexate in children with acute lymphoblastic leukemia and its relation to 6-mercaptopurine pharmacokinetics.
Koren G; Solh H; Klein J; Soldin SJ; Greenberg M
Med Pediatr Oncol; 1989; 17(6):450-4. PubMed ID: 2586358
[TBL] [Abstract][Full Text] [Related]
14. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
[TBL] [Abstract][Full Text] [Related]
15. Serum creatinine and creatinine clearance for predicting plasma methotrexate concentrations after high-dose methotrexate chemotherapy for the treatment for childhood lymphoblastic malignancies.
Xu WQ; Zhang LY; Chen XY; Pan BH; Mao JQ; Song H; Li JY; Tang YM
Cancer Chemother Pharmacol; 2014 Jan; 73(1):79-86. PubMed ID: 24158402
[TBL] [Abstract][Full Text] [Related]
16. Rational use of methotrexate in maintenance therapy of childhood acute lymphoblastic leukemia.
Wang ZH; Yu ZL
Chin Med J (Engl); 1992 Feb; 105(2):147-52. PubMed ID: 1597076
[TBL] [Abstract][Full Text] [Related]
17. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
[TBL] [Abstract][Full Text] [Related]
18. Plasma and urine levels of methotrexate and 7-hydroxymethotrexate in children with ALL during maintenance therapy with weekly oral methotrexate.
Skoglund KA; Söderhäll S; Beck O; Peterson C; Wennberg M; Hayder S; Björk O
Med Pediatr Oncol; 1994; 22(3):187-93. PubMed ID: 8272008
[TBL] [Abstract][Full Text] [Related]
19. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
20. The course of biological parameters and 6-mercaptopurine pharmacokinetics during maintenance treatment of children with acute lymphoblastic leukaemia.
Hayder S; Björk O; Lafolie P
Acta Paediatr Scand; 1990; 79(8-9):832-7. PubMed ID: 2239280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
